Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

Peter Iversen; David G McLeod; William A See; Thomas Morris; Jon Armstrong; Manfred P Wirth; Casodex Early Prostate Cancer Trialists' Group

doi:10.1111/j.1464-410X.2010.09319.x

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

Peter Iversen, David G McLeod, William A See, Thomas Morris, Jon Armstrong, Manfred P Wirth, Casodex Early Prostate Cancer Trialists' Group

91 Citations (Scopus)

Abstract

To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.

Original language	English
Journal	B J U International (Print)
Volume	105
Issue number	8
Pages (from-to)	1074-81
Number of pages	8
ISSN	1464-4096
DOIs	https://doi.org/10.1111/j.1464-410X.2010.09319.x
Publication status	Published - 2010

Keywords

Adult
Aged
Androgen Antagonists
Anilides
Antineoplastic Agents
Disease-Free Survival
Double-Blind Method
Drug Administration Schedule
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Nitriles
Prostatic Neoplasms
Tosyl Compounds

Access to Document

10.1111/j.1464-410X.2010.09319.x

Cite this

Iversen, P., McLeod, D. G., See, W. A., Morris, T., Armstrong, J., Wirth, M. P., & Casodex Early Prostate Cancer Trialists' Group (2010). Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. B J U International (Print), 105(8), 1074-81. https://doi.org/10.1111/j.1464-410X.2010.09319.x

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. / Iversen, Peter; McLeod, David G; See, William A et al.
In: B J U International (Print), Vol. 105, No. 8, 2010, p. 1074-81.

Research output: Contribution to journal › Journal article › Research › peer-review

Iversen, P, McLeod, DG, See, WA, Morris, T, Armstrong, J, Wirth, MP & Casodex Early Prostate Cancer Trialists' Group 2010, 'Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years', B J U International (Print), vol. 105, no. 8, pp. 1074-81. https://doi.org/10.1111/j.1464-410X.2010.09319.x

@article{446cff0617224e8eb7359056990d8064,

title = "Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years",

abstract = "To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.",

keywords = "Adult, Aged, Androgen Antagonists, Anilides, Antineoplastic Agents, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nitriles, Prostatic Neoplasms, Tosyl Compounds",

author = "Peter Iversen and McLeod, {David G} and See, {William A} and Thomas Morris and Jon Armstrong and Wirth, {Manfred P} and {Casodex Early Prostate Cancer Trialists' Group}",

note = "[PETER IVERSEN], [MANFRED P. WIRTH], ASTRAZENECA, [US FEDERAL GOVERNMENT] 2010. JOURNAL COMPILATION {\textcopyright} 2010 BJU INTERNATIONAL.",

year = "2010",

doi = "10.1111/j.1464-410X.2010.09319.x",

language = "English",

volume = "105",

pages = "1074--81",

journal = "B J U International (Print)",

issn = "1464-4096",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "8",

}

TY - JOUR

T1 - Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer

T2 - final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

AU - Iversen, Peter

AU - McLeod, David G

AU - See, William A

AU - Morris, Thomas

AU - Armstrong, Jon

AU - Wirth, Manfred P

AU - Casodex Early Prostate Cancer Trialists' Group

PY - 2010

Y1 - 2010

N2 - To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.

AB - To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy.

KW - Adult

KW - Aged

KW - Androgen Antagonists

KW - Anilides

KW - Antineoplastic Agents

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Follow-Up Studies

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Nitriles

KW - Prostatic Neoplasms

KW - Tosyl Compounds

U2 - 10.1111/j.1464-410X.2010.09319.x

DO - 10.1111/j.1464-410X.2010.09319.x

M3 - Journal article

C2 - 22129214

SN - 1464-4096

VL - 105

SP - 1074

EP - 1081

JO - B J U International (Print)

JF - B J U International (Print)

IS - 8

ER -

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

Abstract

Keywords

Access to Document

Fingerprint

Cite this